Thyrotropin-Secreting Pituitary Microadenoma

Eun Jig Lee\(^1\), Kyung Rae Kim\(^1\), Kyung Mi Lee\(^1\), Doe Heum Yoon\(^2\), Young Soo Kim\(^2\)
Dong Ik Kim\(^1\), Woo He Jung\(^4\), Yoon Sok Chung\(^1\), Sung Kil Lim\(^1\)
Hyun Chul Lee\(^6\) and Kap Bum Huh\(^1\)

We present a 45-yr-old male with clinical signs and symptoms of mild hyperthyroidism, high serum levels of \(T_3\), \(T_4\), and \(FT_3\), as well as serum TSH concentration. The elevated \(a\)-subunit level and \(a\)-subunit/TSH molar ratio were also observed. These findings indicated the presence of hyperthyroidism due to inappropriate secretion of TSH, whose neoplastic origin was documented by nuclear magnetic resonance scan showing a 0.6 cm pituitary adenoma. Selective pituitary adenomectomy was completely successful; \(a\)-subunit, TSH, \(T_3\), \(T_4\), and \(FT_3\) normalized, and euthyroidism was restored. Light microscopic immunohistochemistry showed that the adenoma was composed of TSH-secreting cells.

**Key Words:** TSH-secreting pituitary microadenoma, \(a\)-subunit

TSH-secreting pituitary adenomas first described in 1970 (Hamilton et al.) are uncommon tumors with about 100 cases reported in the medical literature (Gesundheit 1991). Patients with TSH-secreting pituitary adenomas are often misdiagnosed initially, resulting in inappropriate therapy. Hence, most of these tumors usually become large and are invasive at the time of the diagnosis (Lee et al. 1990; Becker et al. 1991). Microadenoma producing TSH is very rare and only 5 cases were reported (Kellett et al. 1983; Mashiter et al. 1983; Gesundheit 1991). Unsuppressed TSH levels in spite of elevated serum thyroid hormone concentrations are characteristic features. Accordingly simultaneous assay of TSH and thyroid hormone in patients with hyperthyroidism is necessary to diagnose TSH-secreting pituitary adenomas (Tolis et al. 1978).

In the present study we report a TSH-secreting pituitary microadenoma in a patient with long standing hyperthyroidism. We examined the effects of hypothalamic releasing hormones and thyroid hormone on hormone release from adenoma in vivo. Light microscopic immunohistochemistry of removed adenoma showed that the adenoma was composed of thyrotropes.

**SUBJECT AND METHODS**

**Case**

In September 1991, a 45-yr-old man was admitted to Yongdong Severance Hospital for evaluation and management of hyperthyroidism. He had been in good health until 1981, when he noted increasing malaise and periodic paralysis. In 1985, weakness of the lower extremity was noted and propylthiouracil was administered for 6 months. In September 1989, the symptoms of hyperthyroidism were developed, \(T_3\) was 270.3 nmol/L (normal values, 64.4~148.0); \(T_4\) 6.9 nmol/L (normal, 1.23~2.46); TSH 7.6 mU/L (normal, 0.25~3.1), and propylthiouracil was readministered until admission.

Physical examination revealed a somewhat hyperactive man with a blood pressure of 140/70...
mmHg. The pulse was regular, with a rate of 88 per minute; the skin was moist, and a fine tremor was noted. The thyroid gland was not enlarged on palpation, and there was no exophthalmos and pretibial pitting edema.

The visual field perimetry revealed no visual field defect. Thyroid function test on admission revealed: T<sub>4</sub> was 226.5 nmol/L; T<sub>3</sub> 3.6 nmol/L; TSH 4.1 mU/L, FT<sub>4</sub> 32 pmol/L (normal, 10.3-25.8), α-subunit 0.96 mU/ml (normal, 0-0.8).

Radiological study with a nuclear magnetic resonance scanning of the sellar turcica, revealed a pituitary microadenoma measuring about 0.6 cm in diameter on the left superior aspect of the pituitary gland (Fig. 1).

In October 1991, The patient underwent selective transphenoidal adenomectomy. After surgery, serum basal TSH, T<sub>3</sub>, T<sub>4</sub>, and FT<sub>4</sub>, were in the normal range, indicating a complete removal of the tumor (Fig. 2).

Clinical studies

The following endocrine tests were performed before surgery: 1) TRH (400 μg, iv); 2) Combined pituitary stimulation with simultaneous injection of LHRH (100 μg, iv), TRH (400 μg, iv), regular insulin (0.15 U/kg, iv); 3) somatostatin (octreotide 50 μg, iv); 4) bromocriptine (5 mg, po); 5) T<sub>3</sub> suppression test (cytomel 75 μg, p.o. daily for 7 days).

Hormonal assay

Serum LH, FSH, PRL, GH, ACTH, FT<sub>3</sub>, cortisol were measured by specific RIA. Serum T<sub>3</sub>, T<sub>4</sub>, FT<sub>4</sub>,
and TSH were measured by ELISA (Boehringer Mannheim GmbH, Mannheim, Germany). Serum α-subunit was measured by immunoradiometric assay (Biocode, Sclœsin, Belgium). The detection limit of the assay was 0.02 mU/ml. The cross-reactivity of free α-subunit in the LH and FSH assays are less than 0.1%. The α-subunit/TSH molar ratio was calculated on the basis of the following mol wt values: TSH, 28,000; and α-subunit, 14,700 (1 μg TSH corresponds to 5 mU).

**Morphological techniques**

A portion of surgically removed pituitary adenoma was fixed immediately after removal. Light microscopic immunohistochemistry was performed using 0.5 μm semithin sections and according to the peroxidase-antiperoxidase method. The antisera used were rabbit antihuman sera for TSHβ, GH, PRL, FSH, LH, and ACTH, which were supplied by the DAKO (Kyoto, Japan).

**RESULTS**

**Clinical studies**

TRH injection induced moderate increase in serum TSH (from 6.3 to 12.4 mU/L) and α-subunit (from 0.53 to 1.3 mU/ml; Fig. 3A). Pituitary hormonal response to combined stimulation gave normal results (PRL, from 7.0 to 18.5 μg/L; LH, from 5.0 to 28.2 U/L; FSH, from 7.7 to 13.9 U/L; GH, from 0.6 to 6.2 μg/L) except in ACTH (41.5 to 6.6 pg/ml) and cortisol (6.3 to 10.2 μg/dl; Table 1).

Somatostatin injection failed to suppress TSH (from 6.5 to 5.6 mU/L) and α-subunit (from 0.96 to 0.60 mU/ml; Fig. 3B).

Bromocriptine ingestion did not suppress TSH (from 7.9 to 7.0 mU/L) and α-subunit (from 0.57 to 0.48 mU/ml; Fig. 3C).

T₄ administration failed to suppress ¹³¹I thyroid uptake at 24 h (from 64 to 64%), but suppressed TSH.

---

**Fig. 3.** TSH and α-subunit release after TRH (A), somatostatin injection (B), bromocriptine ingestion (C), and T₄ and TSH change after a 7-day treatment with T₃ (D).
Thyrotropin-Secreting Pituitary Microadenoma

Table 1. The results of combined stimulation test with TRH (400 μg), Regular insulin (8.0 U), and LH-RH (100 μg).

<table>
<thead>
<tr>
<th>Hormone</th>
<th>Before</th>
<th>30 min</th>
<th>60 min</th>
<th>120 min</th>
<th>180 min</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSH (mU/L)</td>
<td>6.3</td>
<td>7.7</td>
<td>11.0</td>
<td>12.4</td>
<td></td>
</tr>
<tr>
<td>α-subunit (mIU/ml)</td>
<td>0.53</td>
<td>1.30</td>
<td>1.04</td>
<td>0.64</td>
<td></td>
</tr>
<tr>
<td>Prolactin (ng/ml)</td>
<td>7.0</td>
<td>15.7</td>
<td>18.5</td>
<td>6.8</td>
<td></td>
</tr>
<tr>
<td>LH (mIU/ml)</td>
<td>5.0</td>
<td>28.2</td>
<td>26.6</td>
<td>18.5</td>
<td>14.5</td>
</tr>
<tr>
<td>FSH (mIU/ml)</td>
<td>7.7</td>
<td>12.8</td>
<td>26.6</td>
<td>13.4</td>
<td>11.1</td>
</tr>
<tr>
<td>GH (ng/ml)</td>
<td>0.6</td>
<td>0.6</td>
<td>6.2</td>
<td>0.7</td>
<td>0.4</td>
</tr>
<tr>
<td>Cortisol (μg/dl)</td>
<td>6.3</td>
<td>9.9</td>
<td>10.2</td>
<td>4.8</td>
<td>2.7</td>
</tr>
<tr>
<td>ACTH (pg/ml)</td>
<td>41.5</td>
<td>20.3</td>
<td>26.9</td>
<td>6.6</td>
<td>22.9</td>
</tr>
<tr>
<td>Sugar (mg/dl)</td>
<td>70</td>
<td>30</td>
<td>68</td>
<td>75</td>
<td>79</td>
</tr>
</tbody>
</table>

Normal ranges for hormonal values are as follows: TSH, 0.25-3.1 mU/L; α-subunit, 0-0.8 mIU/ml; Prolactin, 4.6-23.0 ng/ml; LH, 5-20 mIU/ml; FSH, 5-20 mIU/ml; GH, <5 ng/ml; Cortisol, 5-25 μg/dl; ACTH <80 pg/ml

Fig. 4. (A) Regular thin fibrous septa surrounding and separating tumor cell nests, some of which showing tubular structure with eosinophilic secretion in the lumen (H&E, ×200). (B) Diffuse positivity for TSH in the cytoplasms of tumor cells (peroxidase antiperoxidase technique, ×200).

Morphological studies

The light microscopic immunohistochemical staining of the adenoma tissue showed that most of the adenoma cells contained TSH β in their cytoplasms (Fig. 4).

DISCUSSION

TSH secreting pituitary adenomas are rarely encountered and represent about 1% of all pituitary adenomas. Most of them reported in the literature were macroadenomas. The microadenomas producing TSH are very rare and only 5 cases have been reported (Kellett et al. 1983; Mashiter et al. 1983; Gesundheit 1991).

For the diagnosis of TSH secreting pituitary adenoma, four criteria should be fulfilled (Tolis et al. 1978). (1) Measurement of a supranormal serum concentration of TSH despite increased concentrations of thyroid hormones. (2) Presence of pituitary tumor. (3) Identification of thyrotropes in the tumor. (4) Disappearance of hyperthyroidism with removal of the pituitary tumor. The finding in our patient of elevated levels of T₃, T₄, and FT₄ and unsuppressed TSH indicated that the negative feedback mechanism was not operative and suggested autonomous TSH overproduction. Nuclear magnetic resonance scan demonstrated a pituitary microadenoma and...
after the transsphenoidal surgery, serum basal TSH, T₄, T₃, and FT₄ were in the normal range. Immunostaining of the removed tumor tissue revealed thyrotrope adenoma.

Several distinctive biochemical features are present in patients with TSH-secreting pituitary adenomas. TSH response to TRH was blunted or absent in 77% of these adenomas (Faglica et al. 1987, Samllridge et al. 1987), but opposite findings were also reported (Fesundheit et al. 1989). In our case, serum TSH increased normally in response to TRH. This responsiveness may be explained by two possible mechanisms. One is that the increased portion of serum TSH was originated not from the adenoma but from the normal functioning thyrotrope. The other is that TSH secretion is not completely independent from the regulatory mechanism in some thyrotrope adenomas. The unresponsiveness to exogenous administration of T₃ was reported in 84% of TSH secreting adenomas (Kourides et al. 1977; Gesundheit et al. 1989). In our patient, exogenous administration of T₃ failed to suppress¹³¹I thyroid uptake and serum T₄, but lowered serum T₃ moderately. It is, however, unclear whether the decreased portion of serum TSH was secreted from the normal thyrotrope or whether the unresponsiveness of¹³¹I thyroid uptake and T₃, despite lowered T₃ levels was due to a high bioactivity of secreted TSH from the adenomatous thyrope.

In addition, measurement of the free α-subunit has proved to be a useful biochemical marker for the presence of a TSH secreting adenoma. TSH is a heterodimeric glycoprotein composed of an α-subunit and a hormone-specific β-subunit; under normal physiologic conditions, the production of these subunits is coordinately regulated. As was shown by Kourides et al. (1977), TSH secreting pituitary adenomas are characterized by excessive production and secretion of α-subunit. The molar ratio in serum of α-subunit to TSH is a good discriminating factor for the diagnosis and the evaluation of treatment of TSH-secreting adenoma. In our patient, serum α-subunit was elevated and the α-subunit/TSH molar ratio was higher than 1.

The α-subunit responsiveness to TRH is almost invariably absent or sluggish in TSH secreting adenoma (Weintraub et al. 1981) However, in our patients, the serum α-subunit showed two fold increase after TRH injection.

In general, serum TSH and α-subunit do not change during manipulation of the dopaminergic tone in TSH secreting adenoma (Kellett et al. 1983), although inhibition of either TSH or α-subunit release by dopamine agonists has been described in some patients (Connel et al. 1982; Beck-Peccoz et al. 1986). The unresponsiveness of TSH to bromocriptine in this patient indicates that he had autonomous TSH release.

Octreotide acetate, the long acting analog of somatostatin (SMS 201-959), has proven to be promising in controlling basal and stimulated thyrotropin secretion from normal and tumorous thyrotropes (Gesundheit 1991; Allyn et al. 1992). Somatostatin infusion caused a slight decrease in basal serum TSH and α-subunit concentration in this patient.

For the diagnosis of TSH secreting adenoma at the early stage, in addition to elevation of the α-subunit tumor marker, high resolution nuclear magnetic resonance scanning with gadolinium may disclose the pituitary abnormality, or inferior petrosal venous sampling may disclose a gradient and lateralization consistent with tumor (Frank et al. 1989; Newton et al. 1989).

The pathogenesis of TSH secreting adenoma has not been elucidated. A hypothalamic basis with excessive TRH production has been suggested (Emerson and Utiger 1972; Kamoi et al. 1985), although the data supporting this view are not compelling. It is unlikely that hypothalamic peptides are directly involved in pituitary DNA mutagenesis and cell transformation. However, persistent hypothalamic stimulation may confer growth advantage to a clone of neoplastic pituitary cells, thus promoting tumor progression. An alternative explanation is that pituitary-specific growth and differentiation factors and protooncogenes may be activated by unknown environmental factors in patients with susceptible genetic background (Gesundheit 1991). Both explanations provide intriguing hypothesis for the pathogenesis of these and other pituitary tumors and are the subject of current investigation.

Surgery is the treatment of choice for TSH secreting pituitary adenomas. Early diagnosis and prompt surgery, preferably by transsphenoidal route, provide the best opportunity for cure. Several patients have been reported who were diagnosed and treated at the stage of a microadenoma (diameter < 1 cm), and these patients have had favorable outcomes (Kellett et al. 1983; Mashiter et al. 1983; Gesundheit 1991). In patients with macroadenomas, surgical therapy is recommended to debulk tumor and permit management by radiotherapy and pharmacotherapy. Although radiation therapy has been used to control further tumor growth, the effi-
cacy of this treatment has not been specifically doc-
umented with TSH secreting adenomas (Gesundheit
1991). Octreotide is an effective therapeutic modal-
ity for reducing TSH hypersecretion secondary to a
pituitary adenoma. Additionally, it has been shown
in four patients to shrink tumors (Gesundheit 1991;
Allyn et al. 1992). In our patient, selective pituitary
adenomectomy was completely successful; α-subu-
unit, TSH, T₃, T₄, and FT₄ normalized, and euthy-
roidism was restored.

REFERENCES

Allyn GSR, Bernstein R, Chynn KY, Kourides IA: Reduc-
tion in size of a thyrotropin- and gonadotropin- se-
creting pituitary adenoma treated with octreotide
acetate (somatostatin analog). J Clin Endocrinol Metab
74: 690-694, 1992

Beck-Peccoz P, Discitelli G, Amr S: Endocrine, biocho-
mycal, and morphological studies of a pituitary
adenoma secreting growth hormone, thyrotropin
(TSH), and α-subunit: evidence for secretion of TSH
with increased bioactivity. J Clin Endocrinol Metab
62: 704-711, 1986

Beckers A, Roger A, Mahler L: Thyrotropin- secreting
pituitary adenomas: report of seven cases. J Clin
Endocrinol Metab 72: 477-483, 1991

Connel S, McCruden DC, Davies DL, Alexander WD:
Bromocriptine for inappropriate thyrotropin secretion.

Emerson CH, Utiger RD: Hyperthyroidism and excessive
thyrotropin secretion, N Engl J Med 287: 328-333,
1972

Faglia G, Beck-Peccoz P, Piscitelli G, Medri G: Inappro-
priate secretion of thyrotropin by the pituitary. Horm

Frank SJ, Gesundheit N, Doppman JL et al: Preoperative
lateralization of pituitary microadenomas by petrosal
sinus sampling: utility in two patients with non-
ACTH-secreting tumors. Am J Med 87: 679-682,
1989

Gesundheit N, Petrik PA, Nissim M, Dahlberg PA,
Doppman JL: Thyrotropin- secreting pituitary ade-
nomas: clinical and biochemical heterogeneity: case
report and follow up of nine patients. Ann Int Med
111(10): 827-835, 1989

Gesundheit N: TSH induced hyperthyroidism. In
Brauerman LE, Utiger RD, ed. Werner and Ingbar's the
thyroid, 6th ed. Philadelphia, JB Lippincott Co,
682-697, 1991

Hamilton GR, Adams LC, Maloof F: Hyperthyroidism
due to thyrotropin producing pituitary chromophobe

Kamoi K, Mitsuma T, Sato H et al: Hyperthyroidism
caused by a pituitary thyrotropin- secreting tumor with
excessive secretion of thyrotropin –releasing
hormone and subsequently followed by Graves' dis-
ease in a middle-aged woman. Acta Endocrino (Copenh)
110(3): 373-377, 1985

Kellett HA, Wylie AH, Dale Bah, Best JJK: Hyper-
thyroidism due to a thyrotropin secreting micro-

Kourides IA, Ridgway EC, Weintraub BD, Bigos STm
Gershengorn MC: Thyrotropin –induced hyper-
thyroidism: use of α and β subunit levels to identify
patient with pituitary tumors. J Clin Endocrinol Metab
45: 534-543, 1977

Lee El, Lee HC, Kim MR, Song YD, Lim SK, Kim KR,
Huh KB: A case of thyrotope adenoma. J Kor Soc
Endocrinol 5: 303-307, 1990

Maschler K, Van Noorden S, Fahlbusch R, Fill H, Skrabul
K: Hyperthyroidism due to a TSH secreting pituitary
adenoma– TSH by morphological cell culture studies.
Clin Endocrinol 18: 473-483, 1983

Newton DR, Dillon WP, Norman D, Newton TH, Wilson
CB: Gd-DTPA-enhanced MR imaging of pituitary

Smallridge RC: Thyrotropin-secreting pituitary tumors.
Endocrinol Metab Clin 16: 765-792, 1987

hyperthyroidism: case report and review of the liter-

Weintraub BD, Gershengorn MC, Kourides IA, Fem H:
Inappropriate secretion of thyroid stimulating hor-